Spanish Breast Cancer Research Group
- Country
- 🇪🇸Spain
- Ownership
- Private
- Established
- 1995-01-01
- Employees
- 101
- Market Cap
- -
- Website
- https://www.geicam.org
Clinical Trials
47
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (34 trials with phase data)• Click on a phase to view related trials
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab
- Conditions
- Locally Advanced Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 2
- Registration Number
- NCT05744375
- Locations
- 🇪🇸
Hospital Universitario de Jeréz De La Frontera, Cádiz, Andalucía, Spain
🇪🇸Hospital Universitario de Jaén, Jaén, Andalucía, Spain
🇪🇸Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
- Conditions
- HER2-positive Metastatic Breast CancerLocally Advanced HER2 Positive Breast Carcinoma
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 13
- Registration Number
- NCT05583110
- Locations
- 🇪🇸
Hospital Universitario de Jeréz De La Frontera, Cádiz, Andalucía, Spain
🇪🇸Hospital Universitario Reina Sofía, Córdoba, Andalucía, Spain
🇪🇸Hospital Universitario de Jaén, Jaén, Andalucía, Spain
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib
- Conditions
- Hormone Receptor PositiveHER2 Positive Breast CancerEarly-stage Breast Cancer
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 177
- Registration Number
- NCT05252988
- Locations
- 🇪🇸
Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸Hospital Costa del Sol, Málaga, Andalucía, Spain
🇪🇸Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 27
- Registration Number
- NCT05063786
- Locations
- 🇦🇹
Medizinische Universität Innsbruck - Univ.Klinik f. Frauenheilkunde Innsbruck, Innsbruck, Austria
🇦🇹LKH Hochsteiermark - Leoben, Leoben, Austria
🇦🇹Ordensklinikum Linz GmbH - BHS, Linz, Austria
Registry Study of Pregnancy and Breast Cancer
- Conditions
- Breast Cancer and Pregnancy
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 1000
- Registration Number
- NCT04603820
- Locations
- 🇪🇸
Hospital Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Universitario Mutua de Terrassa, Terrassa, Barcelona, Spain
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next